Infield Minerals Corp. (TSXV:IN)
Canada · Delayed Price · Currency is CAD | Market Cap | 3.76M +179.4% |
| Revenue (ttm) | n/a |
| Net Income | -277.38K |
| EPS | -0.01 |
| Shares Out | 75.21M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 150,000 |
| Open | 0.0500 |
| Previous Close | 0.0500 |
| Day's Range | 0.0500 - 0.0500 |
| 52-Week Range | 0.0250 - 0.0800 |
| Beta | 1.30 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 18, 2026 |
About Infield Minerals
Infield Minerals Corp. engages in the acquisition, exploration, and evaluation of mineral resource properties in the United States. The company explores for gold and silver deposits. It also holds 100% interest in the Goldendale Property that consist of 172 lode mining claims covering an area of approximately 1,650 acres located in the Nye County, Nevada; and Kings Canyon property in the state of Utah. Additionally, it has an option agreement to acquire 100% interest in the Detroit sediment hosted gold property in Utah. Infield Minerals Corp. i... [Read more]
Financial Performance
Financial StatementsNews
ADAR1 Capital Management, LLC Acquires Additional Shares in InMed Pharmaceuticals Inc
ADAR1 Capital Management, LLC Acquires Additional Shares in InMed Pharmaceuticals Inc
InMed Shares Rise Pre-Market On Mentari's $200 Million Financing Ahead Of Merger
(RTTNews) - InMed Pharmaceuticals Inc. (INM) traded higher by 88% in the pre-market after merger partner Mentari Therapeutics announced a $200 million private placement to advance its migraine prevent...
Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline
WALTHAM, Mass., July 22, 2026 /PRNewswire/ -- Mentari Therapeutics, Inc. ("Mentari"), a privately-held biotechnology company developing therapies for migraine prevention, today announced a $200 millio...
InMed Pharmaceuticals (INM) Moves Forward with Merger Agreement Amendments
InMed Pharmaceuticals (INM) Moves Forward with Merger Agreement Amendments
InMed Pharmaceuticals and Mentari Therapeutics Announce Amendment to Merger Agreement and Filing of Registration Statement on Form S-4
Vancouver, British Columbia and San Francisco, California--(Newsfile Corp. - July 6, 2026) - InMed Pharmaceuticals, Inc. (NASDAQ: INM) ("InMed" or the "Company") today announced that it has entered in...
InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements
Vancouver, British Columbia--(Newsfile Corp. - June 4, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), today announce that it had received written notice from the Listing ...
Squadron Capital Management LLC Acquires 325,000 Shares in InMed Pharmaceuticals Inc
Squadron Capital Management LLC Acquires 325,000 Shares in InMed Pharmaceuticals Inc
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger—D, INM, ESQ, and GDOT
NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and ...
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of InMed Pharmaceuticals, Inc. (NASDAQ: INM)
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and i...
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of InMed Pharmaceuticals, Inc. (Nasdaq – INM)
BALA CYNWYD, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of InMed Pharmaceuticals, Inc. (“InM...
InMed Pharmaceuticals (INM) Soars 170% on Merger with Mentari Therapeutics
InMed Pharmaceuticals (INM) Soars 170% on Merger with Mentari Therapeutics
INM Stock Alert: Halper Sadeh LLC is Investigating Whether InMed Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of InMed Pharmaceuticals, Inc. (NASDAQ: INM) and Mentari Therapeutics, Inc. Upon closing of the pr...
InMed Pharmaceuticals Surges 160% On Merger With Mentari; Amends Preferred Investment Options
(RTTNews) - Shares of InMed Pharmaceuticals, Inc. (INM) jumped 160% following news of a definitive merger agreement with privately held Mentari Therapeutics, Inc., a biotechnology company developing t...
InMed Pharmaceuticals (INM) Merges with Mentari Therapeutics for Migraine Treatment Development
InMed Pharmaceuticals (INM) Merges with Mentari Therapeutics for Migraine Treatment Development
InMed Pharmaceuticals, Mentari Therapeutics To Merge
(RTTNews) - InMed Pharmaceuticals (INM) has entered into a definitive merger agreement for an all-stock transaction with Mentari Therapeutics, a privately-held biotechnology company developing therapi...
InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies
Mentari's parallel lead programs target validated, complementary pathways with potential to address the two-thirds of patients who have a suboptimal response to anti-CGRP therapies Concurrent oversubs...
InMed Pharmaceuticals Amends Preferred Investment Options
Vancouver, British Columbia--(Newsfile Corp. - May 19, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprie...
InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
Vancouver, British Columbia--(Newsfile Corp. - May 6, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of propriet...
InMed Pharmaceuticals Amends Preferred Investment Options
Vancouver, British Columbia--(Newsfile Corp. - April 27, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of propr...
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance
Vancouver, British Columbia--(Newsfile Corp. - March 27, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company developing a pipeline of disease-modifyin...
InMed Pharmaceuticals (INM) Advances Alzheimer's Research with New Preclinical Data
InMed Pharmaceuticals (INM) Advances Alzheimer's Research with New Preclinical Data
InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program
Human Organoid Data Supports the Therapeutic Rationale for INM-901 Program Ahead of Human Clinical Trials Consistent Anti-Inflammatory Effects Demonstrate Translation from Animal Models to Three-Dimen...
InMed Pharmaceuticals (INM) Sets 2026 Development Goals
InMed Pharmaceuticals (INM) Sets 2026 Development Goals
InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial
Advancing Alzheimer's and Age-Related Macular Degeneration Programs Toward FDA Engagement and IND-Enabling Activities Targeting Initiation of Phase 1 Clinical Trial in Alzheimer's Disease in 2027 Vanc...
InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline
Vancouver, British Columbia--(Newsfile Corp. - March 6, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of diseas...